Quinolinic Acid

A metabolite of tryptophan with a possible role in neurodegenerative disorders. Elevated CSF levels of quinolinic acid are correlated with the severity of neuropsychological deficits in patients who have AIDS.

Also Known As:

Networked: 752 relevant articles (26 outcomes, 74 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Guillemin, Gilles J: 30 articles (03/2022 - 01/2002)
2.	Brew, Bruce J: 19 articles (01/2021 - 01/2002)
3.	Kumar, Anil: 11 articles (12/2014 - 11/2009)
4.	Vandresen-Filho, Samuel: 9 articles (10/2018 - 12/2007)
5.	Tasca, Carla I: 8 articles (04/2020 - 04/2005)
6.	Schwarcz, Robert: 8 articles (01/2020 - 01/2003)
7.	Santamaría, Abel: 8 articles (02/2019 - 07/2003)
8.	Kumar, Puneet: 8 articles (09/2017 - 11/2009)
9.	Kalonia, Harikesh: 8 articles (11/2012 - 11/2009)
10.	Braidy, Nady: 7 articles (01/2021 - 07/2009)

Related Diseases

1.	Huntington Disease (Huntington's Disease) 11/01/2000 - "Intrastriatal injection of quinolinate has been proven to be a very useful animal model to study the pathogenesis and treatment of Huntington's disease. " 12/01/2003 - "Deficits induced by quinolinic acid lesion to the striatum in a position discrimination and reversal task are ameliorated by permanent and temporary lesion to the globus pallidus: a potential novel treatment in a rat model of Huntington's disease." 03/16/1998 - "Electrolytic lesion of globus pallidus ameliorates the behavioral and neurodegenerative effects of quinolinic acid lesion of the striatum: a potential novel treatment in a rat model of Huntington's disease." 04/01/2015 - "In this regard, the efficacy of hMSCs transplants in reducing motor and non-motor deficits in a quinolinic acid (QA) rat model of Huntington's disease (HD) was tested in the present study. " 06/01/2015 - "In the present study, the effect of treadmill exercise on spatial-learning ability and motor coordination focusing on the apoptosis in the hippocampus was investigated using quinolinic acid-induced Huntington's disease rats. "
2.	Seizures (Absence Seizure) 06/01/2014 - "Microinjections of quinolinic acid (10 micrograms) or electrical stimulation with 70 Hz frequency produced the paroxysmal manifestations in the form of intensive circular excursions coincident wild running behaviors on the initial nonseizures motor exitation stage of audiogenic seizures. " 10/01/1995 - "Animals that were given quinolinate did not display behavioral seizures, and showed preferential degeneration of neurons in layer V of the entorhinal cortex. " 04/01/1993 - "The unilateral intrahippocampal injection of 120 nmol of quinolinic acid induced seizures together with local neurodegeneration in specific cell layers. " 11/09/1992 - "Low doses of quinolinic acid (QUIN) administered intracerebroventricularly (ICV) to rats produced either no damage or mild to moderate damage in the pyramidal cell layer of the hippocampus and resulted in mild, limbic seizures in the majority of animals treated. " 04/01/1991 - "[Pharmacologic modulation of central noradrenergic mechanisms and the effect of selected substances on chemically-induced seizures: the maximal quinolinic acid seizure test (mouse)]."
3.	Body Weight (Weight, Body) 01/01/2010 - "The optimal dose of Ksheerabala was found from a dose escalation study, wherein it was found that Ksheerabala showed maximum protection against quinolinic acid-induced neurotoxicity at a dose of 15 microL/100 g body weight/day, which was selected for further experiments. " 01/01/2010 - "Four groups of female albino rats were maintained for 21 days as follows: 1. Control group, 2. Quinolinic acid (55 microg/100 g body weight), 3. Ksheerabala (15 microL/100 g body weight), 4. Ksheerabala (15 microL/100 g body weight) + Quinolinic acid (55 microg/100 g body weight). " 04/01/2009 - "As judged from in increase of urinary quinolinic acid and nicotinic acid as indices of metabolic change, NOAEL was 0.1% in diet, corresponding to 90 mg/kg body weight/day, and the lowest-observed-adverse-effect-level (LOAEL) was 0.3% in diet, corresponding to 270 mg/kg body weight/day." 10/01/1997 - "In gerbils, systemic immune activation by an intraperitoneal injection of endotoxin (1 mg/kg of body weight) increased quinolinate levels in brain, blood, lung, liver, and spleen, with proportional increases in lung indoleamine-2,3-dioxygenase activity at 24 h postinjection. " 11/01/2012 - "Minocycline (25, 50, and 100 mg/kg) treatment (for 21 days) significantly improved body weight, locomotor activity, rotarod performance, balance beam walk performance, oxidative defense, attenuated TNF-α and IL-6 levels as compared to quinolinic-acid (QA)-treated animals. "
4.	Acquired Immunodeficiency Syndrome (AIDS) 12/01/1995 - "Quinolinic acid and neurodegeneration in AIDS." 06/01/1993 - "Quantitation of human immunodeficiency virus, immune activation factors, and quinolinic acid in AIDS brains." 01/01/1991 - "Cerebrospinal fluid quinolinic acid concentrations are increased in acquired immune deficiency syndrome." 08/01/1989 - "It remains to be determined whether increased brain quinolinic acid concentrations are involved in the pathogenesis of the neuropathology of AIDS." 08/01/1989 - "Cerebrospinal fluid quinolinic acid concentrations are increased in acquired immune deficiency syndrome."
5.	Neuroinflammatory Diseases 05/01/2014 - "Inhibitors of quinolinic acid synthesis: new weapons in the study of neuroinflammatory diseases." 09/18/2021 - "We evaluated target engagement and the effects of CYR119 on markers of neuroinflammation in vitro in mouse microglial cells and in vivo in quinolinic acid (QA)-induced and high-fat diet-induced rodent neuroinflammation models. " 01/01/2021 - "[18 F]5 was stable in rat plasma for at least 4 h and was evaluated by μPET imaging and biodistribution using a unilateral quinolinic acid rat model of neuroinflammation. " 09/17/2015 - "As a positive control for neuroinflammation, we performed unilateral intrastriatal injection of quinolinic acid (QA) in a separate group of WT rats. " 04/01/2012 - "Over the last two decades, evidence for the involvement of quinolinic acid (QUIN) in neuroinflammatory diseases has been exponentially increasing. "

Related Drugs and Biologics

1.	Kynurenine
2.	Tryptophan (L-Tryptophan)
3.	N-Methylaspartate (NMDA)
4.	Enzymes
5.	Nitrites
6.	salicylhydroxamic acid (SHAM)
7.	Catalase
8.	Neurotoxins
9.	N-Methyl-D-Aspartate Receptors (NMDA Receptors)
10.	Interleukin-6 (Interleukin 6)

Related Therapies and Procedures

1.	Transplantation
2.	Injections
3.	Therapeutics
4.	Intraperitoneal Injections
5.	Moxibustion